| Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice A Gajra, A Zalenski, A Sannareddy, Y Jeune-Smith, K Kapinos, ... Pharmaceutical Medicine 36 (3), 163-171, 2022 | 40 | 2022 |
| Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma (RRMM) who have received a prior BCMA … CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood 140 (Supplement 1), 1856-1858, 2022 | 13 | 2022 |
| Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T therapy LC Peres, LB Oswald, C Dillard, G De Avila, T Nishihori, BJ Blue, ... Blood 140 (Supplement 1), 623-625, 2022 | 11 | 2022 |
| Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience D Dima, JA Davis, N Ahmed, X Jia, A Sannareddy, H Shaikh, L Shune, ... Transplantation and cellular therapy 30 (3), 308. e1-308. e13, 2024 | 10 | 2024 |
| Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study D Dima, A Sannareddy, N Ahmed, JA Davis, H Shaikh, Z Mahmoudjafari, ... Blood 142, 3330, 2023 | 6 | 2023 |
| Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma D Dima, JA Davis, N Ahmed, A Sannareddy, H Shaikh, Z Mahmoudjafari, ... Blood 142, 91, 2023 | 6 | 2023 |
| Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal insufficiency: Real world experience S Sidana, LC Peres, H Hashmi, H Hosoya, CJ Ferreri, S Atrash, J Khouri, ... Blood 140 (Supplement 1), 10377-10379, 2022 | 6 | 2022 |
| Factors associated with refractoriness or early progression after idecabtagene vicleucel (Ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM): US Myeloma CAR … H Hashmi, DK Hansen, LC Peres, OA Castaneda Puglianini, CL Freeman, ... Blood 140 (Supplement 1), 4642-4645, 2022 | 6 | 2022 |
| Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the US Myeloma Immunotherapy Consortium A Afrough, H Hashmi, DK Hansen, S Sidana, C Ahn, LC Peres, D Dima, ... Blood Cancer Journal 14 (1), 63, 2024 | 3 | 2024 |
| Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience S Sidana, L Peres, H Hashmi, H Hosoya, C Ferreri, S Atrash, J Khouri, ... 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023 | 3 | 2023 |
| Toxicity of CAR T-Cell Therapy for Multiple Myeloma A Afrough, PR Abraham, L Turer, G Kaur, A Sannareddy, DK Hansen, ... Acta Haematol, 2024 | 1 | 2024 |
| Pre-Lymphodepletion Endothelial Activation and Stress Index As a Predictor of Clinical Outcomes in B-Cell Maturation Antigen CAR T Therapy for Multiple Myeloma J Lee, HV Upreti, A Sannareddy, H Reves, L Turer, P Abraham, Y Liu, ... Transplantation and Cellular Therapy 30 (2), S221-S222, 2024 | 1 | 2024 |
| Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis A Sannareddy, L Turer, J Lee, K Gaines, H Patel, P Abraham, A Jones, ... Blood 142, 6921, 2023 | 1 | 2023 |
| HSR22-178: real world outcomes of cancer patients with SARS-CoV-2 infection receiving monoclonal antibodies A Wilden, A Sannareddy, H Patel, S Kansagra, G Kaur, P Ramakrishnan, ... Journal of the National Comprehensive Cancer Network 20 (3.5), HSR22-178 …, 2022 | 1 | 2022 |
| T-Cell Telomere Length As a Biomarker to Predict Outcome in Patients Receiving CAR-T Immunotherapy E Tedone, M Sayed, TP Lai, A Sannareddy, DP Ramasamy, ... Blood 138, 4798, 2021 | 1 | 2021 |
| Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy D Dima, U Goel, A Sannareddy, N Ibeh, F Ullah, A Afrough, S Mazzoni, ... Hematological Oncology 42 (4), e3293, 2024 | | 2024 |
| Current Novel Targeted Therapeutic Strategies in Multiple Myeloma CHT Lin, MJ Tariq, F Ullah, A Sannareddy, F Khalid, H Abbas, A Bader, ... International Journal of Molecular Sciences 25 (11), 6192, 2024 | | 2024 |
| Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience from the US Myeloma Innovations Research Collaborative (USMIRC) D Dima, J Davis, N Ahmed, X Jia, A Sannareddy, H Shaikh, L Shune, ... Transplantation and cellular therapy 30 (2), S384, 2024 | | 2024 |
| Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A … D Dima, J Davis, N Ahmed, A Sannareddy, H Shaikh, L Shune, G Kaur, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single Center Retrospective Analysis. A Sannareddy, J Lee, HV Upreti, L Turer, JM Anderson, H Reves, ... Transplantation and Cellular Therapy 30 (2), S430, 2024 | | 2024 |
